Chairman
GoodRx Holdings, Inc. (GDRX)Board Member
GoodRx Holdings, Inc. (GDRX)Equibles does not estimate personal net worth.
Get an email with a short summary when GoodRx Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get GDRX alertsScott Wagner is recorded as Chairman at GoodRx Holdings, Inc. (GDRX) since January 21, 2025, Board Member at GoodRx Holdings, Inc. (GDRX) since January 1, 2025 and CEO at GoodRx Holdings, Inc. (GDRX). The newest filing on record that lists Scott Wagner as CEO and Board Member at GoodRx Holdings, Inc. (GDRX) is dated April 29, 2026. GoodRx Holdings, Inc. reported in an 8-K filed January 22, 2025 that Scott Wagner was appointed Chair of the Board's Compensation Committee, effective January 21, 2025. GoodRx Holdings, Inc. reported in an 8-K filed January 22, 2025 that Scott Wagner was appointed Class II director, effective January 21, 2025. GoodRx Holdings, Inc. reported in an 8-K filed April 25, 2023 that Scott Wagner was appointed Interim Chief Executive Officer, effective April 25, 2023. The proxy statement of GoodRx Holdings, Inc. reports total compensation of $856,780 for Scott Wagner in fiscal 2025, including a base salary of $42,788. Disclosed compensation is on record for 3 fiscal years. Scott Wagner has spoken on 7 earnings calls across 1 company, most recently for GoodRx Holdings, Inc. on November 7, 2024. GoodRx Holdings, Inc. is classified in the Health Information Services industry within the Healthcare sector. Other leadership on record at GoodRx Holdings, Inc. includes Wendy Barnes (CEO and Board Member), Trevor Bezdek (Chairman), Christopher A. McGinnis (CFO) and 7 others.
“The Board also appointed Mr. Wagner as the Chair of the Board's Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.”
“On January 21, 2025, the Board of Directors (the "Board") of GoodRx Holdings, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company.”
“Thanks, Aubrey, and thanks to everyone for joining us today to discuss our third quarter results. Our Q3 top line was where we expected and adjusted EBITDA margin came in higher than we anticipated.”
“Thanks, Aubrey, and thanks everyone for joining us today to discuss our second quarter results.”
“Thanks, Whitney, and thanks to everyone joining us today to discuss our first quarter results. Today I'd like to highlight the meaningful headway we've made over the last 12 months and more specifically in the first quarter.”
“Thanks, Whitney, and thanks to everyone joining us today to discuss our fourth quarter results. Today, I'd like to highlight the meaningful progress we're making on our key priorities, and then Karsten will take you through our Q4 '23 financials and expectations for Q1 and the full year 2024.”
“Thanks, Whitney, and thanks to everyone for joining us today to discuss our third quarter results. Today I'd like to highlight the meaningful progress we're making against our top priorities, and then Karsten will take you through the Q3 results.”
SEC 8-K
2025-01-21–present
2025-01-21–present
2025-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
Health Information Services · Healthcare
CEO, Chairman, Board Member
2025-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GoodRx Holdings, Inc. (GDRX) | Former Interim Chief Executive Officer | $42,788 | $856,780 |
| 2024 | GoodRx Holdings, Inc. (GDRX) | Interim Chief Executive Officer | $750,000 | $9,767,472 |
| 2023 | GoodRx Holdings, Inc. (GDRX) | Interim Chief Executive Officer | $511,538 | $10,144,526 |
